iosBio has ongoing collaborations with a number of pharmaceutical companies:

• GSK: iosBio has entered into an option and license agreement with GSK to evaluate the company’s thermal stability platform technology
• Zoetis: Zoetis (formerly Pfizer Animal Health) and iosBio entered a three-year collaboration to explore the potential of the company’s technologies in biopharmaceuticals and vaccines for animals
• Oncolytic biotech [confidential]: iosBio entered into an option and license agreement with a confidential oncolytic biotech company to stabilize their lead clinical asset

iosBio seeks further partnership opportunities with pharma and biotech companies on:

• iosBio’s internal pipeline
• Therm-SB: providing thermal stability to partners assets (vaccines, vectors, viruses)
• OraPro: efficaciously delivering partners vectors to the GI tract to transduce DNA products for host cells

Please contact [contact details]